<PAGE>
/------------------------------/
/ OMB APPROVAL /
/------------------------------/
/ OMB Number:............... /
/ Expires:.................. /
/ Estimated average burden.. /
/ Hours per response........ /
/------------------------------/
+--------+
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION
+--------+ Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
(Print or Type Response)
- --------------------------------------------------------------------------------
1. Name and Address of Reporting Person*
Ocular Sciences, Inc. ("OSI")
----------------------------------------------------------------------------
(Last) (First) (Middle)
475 Eccles Avenue
----------------------------------------------------------------------------
(Street)
South San Francisco CA 94080
----------------------------------------------------------------------------
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year) 3/19/00
--------------
3. IRS or Social Security Number of Reporting Person
(Voluntary)
--------------
4. Issuer Name and Ticker or Trading Symbol Wesley Jessen VisionCare, Inc.
("WJ") Nasdaq - "WJCO"
-----------------------------------
5. Relationship of Reporting Person to Issuer (Check all applicable)
[_] Director [_] Officer [X] 10% Owner [_] Other
(give title below) (specify below)
----------------------------------------------------------------------------
6. If Amendment, Date of Original (Month/Day/Year)
----------------------------
7. Individual or Joint/Group Filing (Check Applicable Line)
[X] Form filed by One Reporting Person
[_] Form filed by More than One Reporting Person
Table I--Non-Derivative Securities Beneficially Owned
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------
1. Title 2. Amount of 3. Ownership Form: 4. Nature of
of Securities Bene- Direct (D) or Indirect Bene-
Security ficially Owned Indirect (I) ficial Ownership
(Instr. 4) (Instr. 4) (Instr. 5) (Instr. 5)
- --------------------------------------------------------------------------------
<S> <C> <C> <C>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
5(b)(v).
Table II--Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------------
1. Title of Derivative 2. Date Exer- 3. Title and Amount of Securities 4. Conversion 5. Ownership 6. Nature of In-
Security (Instr. 4) cisable and Underlying Derivative Security or Form of direct Bene-
Expiration (Instr. 4) Exercise Derivative ficial
Date Price Security: Ownership
(Month/Day/ of Direct (D) (Instr. 5)
Year) Derivative or In-
---------------------------------------------------- Security direct (I)
Date Expira- Amount or (Instr. 5)
Exer- tion Title Number of
cisable Date Shares
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C>
Option (Right to Purchase) (a) (b) Common Stock 3,506,397 25.00 D (c)
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
Explanation of Responses:
(a) The option referenced above was granted in connection with an
Agreement and Plan of Merger, dated March 19, 2000, among WJ, OSI and
OSI Acquisition Corp. The option is not currently excercisable. The
option may be exercised by OSI at any time after the occurrence of an
event the result of which is that the total fee required to be paid to
OSI pursuant to Section 7.2 of the merger agreement equals $20.0
million.
(b) The option is scheduled to expire upon the earlier of:(i) the
effective time of the merger, (ii) six months after the first
occurrence of an event that entitles OSI to receive the termination
fee set forth in the merger agreement, (iii) the termination of the
merger agreement under circumstances in which no termination fee is
payable or (iv) 12 months after the date the merger agreement is
terminated if OSI is entitled to receive termination fees under
Section 7.2(b)(A) thereof.
(c) OSI expressly disclaims beneficial ownership of all shares of WJ
Common Stock that may be purchased upon the exercise of the option.
Ocular Sciences, Inc.
/s/ Gregory Lichtwardt 3/28/00
------------------------------- -----------------
**Signature of Reporting Person Date
Name: Gregory Lichtwardt
Title: Chief Financial Officer
** Intentional misstatements or omissions of facts constitute Federal
Criminal Violations.
Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently
valid OMB Number.
SEC 1473 (7-96) Page 2
